Intervention not reported
3MSC: change in 3MSC rates (stairs/min) from baseline · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
6MWT: change from baseline in m walked · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
Respiratory tests: absolute change from baseline in FVC (L) · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
Cardiac function  · children and adults with mucopolysaccharidosis type VI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
GAG level: change in urinary GAG level from baseline ųg/mg creatinine · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
AEs: drug‐related AEs · children and adults with mucopolysaccharidosis type VI
It is very uncertain whether the intervention changes AEs: drug‐related AEs (very low certainty).
1 finding from 1 review
Treatment withdrawal · people with epilepsy
1 finding from 1 review
Adverse effects (cardiac) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (cardiac) compared with levetiracetam (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (gastrointestinal) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (bones and muscles) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (bones and muscles) compared with levetiracetam (low certainty).
1 finding from 1 review
Adverse effects (others) · participants with epilepsy (BECTS)
Sulthiame showed no clear difference in adverse effects (others) compared with levetiracetam (low certainty).
1 finding from 1 review
Treatment withdrawal · participants with epilepsy (GTCS)
1 finding from 1 review
Seizure freedom · participants with epilepsy (GTCS)
1 finding from 1 review
All adverse effects · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in all adverse effects compared with phenytoin (low certainty).
1 finding from 1 review
Paraesthesia · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in paraesthesia compared with phenytoin (low certainty).
1 finding from 1 review
Dizziness · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in dizziness compared with phenytoin (low certainty).
1 finding from 1 review
Headache · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in headache compared with phenytoin (low certainty).
1 finding from 1 review
Seizure freedom · people with epilepsy
1 finding from 1 review
Anorexia · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in anorexia compared with phenytoin (low certainty).
1 finding from 1 review
Rash · participants with epilepsy (GTCS)
Sulthiame showed no clear difference in rash compared with phenytoin (low certainty).
1 finding from 1 review